SCHEMBL5855192

SCHEMBL5855192

CC(=O)CC(=O)OCC(=O)Nc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 3/20 0.59
MAPT P10636 4/20 0.58
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HPGD P15428 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
ALOX12 P18054 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 1/20 0.55
POLB P06746 1/20 0.55
KMT2A Q03164 1/20 0.55
ATM Q13315 1/20 0.53
NOTUM Q6P988 1/20 0.53
USP2 O75604 1/20 0.52
PABPC1 P11940 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10983201 0.85 KLK7 (0.61) KLK7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL4594156 0.84 SMN1; SMN2 (0.74) KLK7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11235408 0.81 KLK7 (0.59) KLK7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL13333919 0.81 KLK7 (0.59) KLK7MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL10694410 0.80 KLK7 (0.76) KLK7NPC1RAB9ASMN1; SMN2L3MBTL1
SCHEMBL14914 0.80 MAPT (0.85) MAPTL3MBTL1HTTALDH1A1MEN1
SCHEMBL9121361 0.80 MAPT (0.85) MAPTL3MBTL1HTTALDH1A1MEN1
SCHEMBL8849064 0.78 MAPT (0.82) MAPTL3MBTL1HTTALDH1A1MEN1
SCHEMBL28996270 0.78 MAPT (0.82) MAPTL3MBTL1HTTALDH1A1MEN1
Potassium SCHEMBL30309050 0.78 MAPT (0.82) MAPTL3MBTL1HTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103570919-B Self-sensitive photopolymerisable liquid resin and use thereof ETERNAL CHEMICAL CO.,LTD. (CN) 2016-03-23 CN disclosed
US-6995179-B2 Dihydropyridine derivative AJINOMOTO CO., INC. (JP) 2006-02-07 US disclosed
US-20020111494-A1 Novel dihydropyridine derivative AJINOMOTO CO., INC. (JP) 2002-08-15 US disclosed
US-6350766-B1 PAIN, CNS AJINOMOTO CO., INC. (JP) 2002-02-26 US disclosed
EP-0985667-A1 NOVEL DIHYDROPYRIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2000-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111494-A1 Novel dihydropyridine derivative CACNA1B, CACNA1D, CACNA1S KLK7 4575/4885MAPT 177/4885NPC1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.